Top ▲

Glycine transporter subfamily C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Click here for help

« Hide

Two gene products, GlyT1 and GlyT2, are known that give rise to transporters that are predominantly located on glia and neurones, respectively. Five variants of GlyT1 (a,b,c,d & e) differing in their N- and C-termini are generated by alternative promoter usage and splicing, and three splice variants of GlyT2 (a,b & c) have also been identified (see [5,12,14,37] for reviews). GlyT1 transporter isoforms expressed in glia surrounding glutamatergic synapses regulate synaptic glycine concentrations influencing NMDA receptor-mediated neurotransmission [4,13], but also are important, in early neonatal life, for regulating glycine concentrations at inhibitory glycinergic synapses [15]. Homozygous mice engineered to totally lack GlyT1 exhibit severe respiratory and motor deficiencies due to hyperactive glycinergic signalling and die within the first postnatal day [15,38]. Disruption of GlyT1 restricted to forebrain neurones is associated with enhancement of EPSCs mediated by NMDA receptors and behaviours that are suggestive of a promnesic action [43]. GlyT2 transporters localised on the axons and boutons of glycinergic neurones appear crucial for efficient transmitter loading of synaptic vesicles but may not be essential for the termination of inhibitory neurotransmission [16,35]. Mice in which GlyT2 has been deleted develop a fatal hyperekplexia phenotype during the second postnatal week [16] and mutations in the human gene encoding GlyT2 (SLC6A5) have been identified in patients with hyperekplexia (reviewed by [17]). ATB0+ (SLC6A14) is a transporter for numerous dipolar and cationic amino acids and thus has a much broader substrate specificity than the glycine transporters alongside which it is grouped on the basis of structural similarity [10]. ATB0+ is expressed in various peripheral tissues [10]. By contrast PROT (SLC6A7), which is expressed only in brain in association with a subset of excitatory nerve terminals, shows specificity for the transport of L-proline.

Transporters

936
Click here for help

GlyT1 / SLC6A9 C Show summary » More detailed page go icon to follow link

GlyT2 / SLC6A5 C Show summary »


Target Id 936
Nomenclature GlyT2
Systematic nomenclature SLC6A5
Previous and unofficial names Glycine transporter 2 | NET1 | sodium- and chloride-dependent glycine transporter 2 | solute carrier family 6 (neurotransmitter transporter, glycine), member 5 | solute carrier family 6 (neurotransmitter transporter), member 5 | solute carrier family 6 (neurotransmitter transporter
Genes SLC6A5 (Hs), Slc6a5 (Mm), Slc6a5 (Rn)
Ensembl ID ENSG00000165970 (Hs), ENSMUSG00000039728 (Mm), ENSRNOG00000031662 (Rn)
UniProtKB AC Q9Y345 (Hs), Q761V0 (Mm), P58295 (Rn)
Bioparadigms SLC Tables SLC6A5 (Hs)
Endogenous substrates
glycine
Inhibitors
bitopertin pEC50 <4.5 [33]
GT-0198 pIC50 8.8 [30]
opiranserin pIC50 6.1 [29]
Selective inhibitors
Org 25543 pIC50 7.8 [9]
ALX 1393 pIC50 7.0 [27]
ALX 1405
Stoichiometry 3 Na+: 1 Cl-: 1 glycine
Comment N-Oleoyl-L-carnitine (0.3μM, [8]) and and N-arachidonoylglycine (IC50 5-8 µM, [42]) have been described as potential endogenous selective GlyT2 inhibitors

ATB0,+ / SLC6A14 C Show summary »

PROT / SLC6A7 C Show summary »

Comments

Click here for help

Show »

References

Click here for help

Show »

NC-IUPHAR subcommittee and family contributors

Show »

How to cite this family page

Database page citation (select format):

Concise Guide to PHARMACOLOGY citation:

Alexander SP, Kelly E, Mathie A, Peters JA, Veale EL et al. (2021) THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. Br J Pharmacol. 178 Suppl 1:S412-S513.